Compare Adaptive Biotechnologies Corp (ADPT) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Tesla, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.19 (market cap $4.04B), while Tesla, Inc. trades at $331.2 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 324.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | TSLA | |
|---|---|---|
Market Cap | $4.04B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $489.88 |
52-Week Low | $12.30 | $298.16 |
Enterprise Value | $4.10B | $1.29T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Tesla (TSLA) trades at $330.87, up 0.7% on the day, with a bearish technical signal from moving averages and a mixed fundamental picture. The stock shows high valuation multiples (P/E 308.16, P/S 11.36) amid declining profitability, with net income margin falling to 3.67% in 2025 from 15.49% in 2023. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, but Q2 2026 earnings missed expectations.
Outlook remains polarized: analyst consensus price target of $393.87 suggests 19% upside, but high valuation and margin compression pose risks. Key catalysts include autonomy advancements and energy/robotics growth, while competition and execution challenges weigh on sentiment. The stock's trajectory hinges on delivering AI-driven revenue streams beyond automotive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
